Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bimagrumab

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Eli Lilly · Phase 2 · Withdrawn · Enrollment 0

NCT06901349

ArmPopulationDoseWeeksEstimandWeight change
Bimagrumab Dose 1 + Tirzepatide PlaceboObesity or overweightn/rn/rn/rn/r
Bimagrumab Dose 2 + Tirzepatide PlaceboObesity or overweightn/rn/rn/rn/r
Tirzepatide Dose 1 + Bimagrumab PlaceboObesity or overweightn/rn/rn/rn/r
Tirzepatide Dose 2 + Bimagrumab PlaceboObesity or overweightn/rn/rn/rn/r
Bimagrumab Dose 2 + Tirzepatide Dose 1Obesity or overweightn/rn/rn/rn/r
Bimagrumab Dose 1 + Tirzepatide Dose 1Obesity or overweightn/rn/rn/rn/r
Bimagrumab Dose 2 + Tirzepatide Dose 2Obesity or overweightn/rn/rn/rn/r
Bimagrumab Dose 1 + Tirzepatide Dose 2Obesity or overweightn/rn/rn/rn/r
Bimagrumab Placebo + Tirzepatide PlaceboObesity or overweightn/rn/rn/rn/r